Nordic Nanovector Asa
Nordic Nanovector Asa's email is mail@nordicnanovector.com
and
Nordic Nanovector Asa's phone number is +47 22 18 33 01
.
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD3...
read more
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
show less
Website | nordicnanovector.com | |
Industry | Biotechnology | |
Location | Oslo, Oslo, Norway | |
Employees | 44 | |
Founded | 2009 |
HQ | Kjelsåsveien 168 B | |
Phone | +47 22 18 33 01 | |
mail@nordicnanovector.com | ||
Funding | 29,885,866 USD | |
Competitors | Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences, |
Website | nordicnanovector.com | |
Industry | Biotechnology | |
Location | Oslo, Oslo, Norway | |
Employees | 44 | |
Founded | 2009 | |
linkedin.com/company/nordic-nanovector-as | ||
HQ | Kjelsåsveien 168 B | |
Phone | +47 22 18 33 01 | |
mail@nordicnanovector.com | ||
Funding | 29,885,866 USD |
Email Patterns for Nordic Nanovector Asa
Top Competitors for Nordic Nanovector Asa
Nordic Nanovector Asa Questions
Where are Nordic Nanovector Asa's headquarters?
Nordic Nanovector Asa's headquarters are in Kjelsåsveien 168 B
What is Nordic Nanovector Asa's phone number?
Nordic Nanovector Asa's phone number is +47 22 18 33 01
What is Nordic Nanovector Asa's official website?
Nordic Nanovector Asa's website is nordicnanovector.com
How many employees are working in Nordic Nanovector Asa right now?
Nordic Nanovector Asa has
44 employees.
View the Email and Phone Numbers for all 44 working at Nordic Nanovector Asa.
What is Nordic Nanovector Asa's industry?
Nordic Nanovector Asa's industry is
Biotechnology
Who are Nordic Nanovector Asa's top competitors?
Nordic Nanovector Asa's top competitors are
Roche
,
Agilent Technologies
,
Amgen
,
Genentech
,
Eurofins
,
Gilead Sciences
What is Nordic Nanovector Asa's email address?
Nordic Nanovector Asa's email address is mail@nordicnanovector.com
What are Nordic Nanovector Asa's categories?
Nordic Nanovector Asa's categories are Biotechnology, Life Science, Medical
What is Nordic Nanovector Asa's location?
Nordic Nanovector Asa's location is
Oslo, Oslo, Norway
When was Nordic Nanovector Asa's founded?
Nordic Nanovector Asa's founding year is 2009
What is Nordic Nanovector Asa's funding?
Nordic Nanovector Asa's funding is 29,885,866 USD
What is Nordic Nanovector Asa's current status?
Nordic Nanovector Asa's current status is ipo
Top Nordic Nanovector Asa Employees
Medical Science Liaison
mrkovak@gmail.com
+1724-778-0058
Chief Quality Officer
rosemarie.corrigan@thrombogenics.com
+321-675-1310
Qa Manager
+44794-620-3582
Associate Director Clinical Quality Assurance
julie.kelly@tmqa.co.uk
Clinical Research Support Manager
marianne.fugli@algeta.com
Executive Assistant And Human Resources Coordinator
sbeeck@specificmedia.com
Clinical Research Administrator
tgreil@nordicnanovector.com